alexa
Reach Us +44-1647-403003
Home Parenteral Nutrition (HPN) In Cancer And The Suitability Of Prescribtion Based On The Duration Of Therapy | 15832
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Home Parenteral Nutrition (HPN) in cancer and the suitability of prescribtion based on the duration of therapy

3rd World Congress on Cancer Science & Therapy

Michela Zanardi

ScientificTracks: J Cancer Sci Ther

DOI: 10.4172/1948-5956.S1.028

Abstract
This lecture will address topics about Home Parenteral Nutrition (HPN) in palliative oncological patients, often hypo- aphagic or in whom oral nutrition is contraindicated because mechanical intestinal obstruction. In fact, in patients with cancer, parenteral nutrition is controversial, although many studies have shown it is able to slow the loss of weight, restore the heritage protein, enhance and prolong survival. According to the main guidelines and evidences, in incurable malnourished cancer patients, palliative home parenteral nutrition should be start if the probability to die from starvation is superior to that of dying from tumor spread, if expected survival is longer than two/three months, if Karnofsky Performance score is more than 50 (patients capable of self-care), if the intake of nutrients by mouth drops to about 60% for a period equal to or more than 10 days and if enteral nutrition is not feasible. The aim is not the rehabilitation, but to guarantee the functionality of vital organs and to improve the quality of life, by reducing physical, psychological and spiritual distress, even thanks to a performance status recovery. The decision to utilize parenteral nutrition in patients with advanced cancer is difficult not only because it assumes the existence of clinical requirements, but also the availability of its management by the patient and family. Data about a study conducted in my clinical nutrition unit on HPN duration in oncological patients will be presented and some consideration on indications of starting or stopping, if already started, an oncological HPN will be done.
Biography
Michela Zanardi is a Physician specialist in clinical nutrition, working in an hospital of Turin, Professor of Oncology and Nutrition Science at the degree of Dietetics, Pediatric Nursing and Midwives, in the Working Group of Italian Dieticians Association (ADI) on hospital artificial nutrition. Participation as a speaker at numerous conferences and training courses on various aspects of nutrition (artificial nutrition, role of food on prevention of cardiovascular and oncological diseases, malnutrition, waste food) author of publications (abstracts, books, original articles).
Relevant Topics
Top